Oral glycoprotein iib/iiia inhibitors why don't they work?

American Journal of Cardiovascular Drugs

Volumn 1, Issue 6, 2001, Pages 421-428

  Chew, Derek P ^a   Bhatt, Deepak L ^a   Topol, Eric J ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Desk F25 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR;

APOPTOSIS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; HEART MUSCLE ISCHEMIA; HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADMINISTRATION, ORAL; APOPTOSIS; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS;

EID: 0005731857     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/00129784-200101060-00002     Document Type: Article

References (35)

1. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists? Collaboration. BMJ 1994; 308: 81-106
2. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39
3. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (7): 494-502
4. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338: 1498-505
5. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338: 1488-97
6. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 1998; 339: 436-43
7. Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet receptor inhibition in ischemic syndrome management. Lancet 1999; 354: 1757-62
8. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-61
9. Simpfendorfer C, Kottke-Marchant K, Lowrie M, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997; 96: 76-81
10. Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997; 96: 1117-21
11. Kereiakes DJ, Runyon JP, Kleiman NS, et al. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Circulation 1996; 94: 906-10
12. Kereiakes DJ, Kleiman NS, Ferguson JJ, et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation 1998; 98: 1268-78
13. Cannon CP, McCabe CH, Borzak S, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in myocardial infarction. Circulation 1998; 97: 340-9
14. Harrington RA, Armstrong PW, Graffagnino C, et al. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease [In Process Citation]. Circulation 2000; 102: 728-35
15. Akkerhuis KM, Neuhaus KL, Wilcox RG, et al. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Eur Heart J 2000; 21: 2042-55
16. O?Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 2000; 342: 1316-24
17. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102: 149-56
18. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000; 355: 337-45
19. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 2001; 103: 1727-33
20. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103: 201-6
21. Heeschen C, Hamm CW. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists. Lancet 2000; 355: 330-1
22. Ginsberg MH, Xiaoping D, O?Toole TE, et al. Platelet integrins. Thromb Haemost 1993; 70: 87-93
23. Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc Res 2000; 45: 437-46
24. Holmes M, Sobel BE, Cannon CP, et al. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome. An OPUS-TIMI 16 substudy. Am J Cardiol 2000; 85: 491-3
25. Du XP, Plow EF, Frelinger AL, et al. Ligands ?activate? integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell 1991; 65: 409-16
26. Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alpha IIb beta 3) inhibitors. Blood 1998; 92: 3240-9
27. Gawaz M, Ruf A, Neumann FJ, et al. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 1998; 80: 994-1001
28. Kereiakes DJ. Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy? Am Heart J 1999; 138: S39-46
29. Steinhubl S, Talley D, Kereiakes D, et al. A prospective multicentre study to determine the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary interventin-the GOLD study. J Am Coll Cardiol 2000; 35: 44A
30. Akkerhuis M, van der Zwaan C, Wilcox R, et al. Troponin-I identifies patients with unstable coronary artery disease who benefit from long-term oral glycoprotein IIb/IIIa inhibition. Circulation 1999; 100: I-292
31. Kastrati A, Schomig A, Seyfarth M, et al. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999; 99: 1005-10
32. Cooke G, Liu-Stratton Y, Frid D, et al. Pharmacogenomics: response to aspirin is dose, agonists and PLA dependent. J Am Coll Cardiol 2001; 37: 276A
33. Cook SA, Poole-Wilson PA. Cardiac myocyte apoptosis. Eur Heart J 1999; 20: 1619-29
34. Adderley SR, Fitzgerald DJ. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J Biol Chem 2000; 275: 5760-6
35. Buckley CD, Pilling D, Henriquez NV, et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature 1999; 397: 534-9